Salipro Biotech inks deal with Boehringer

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today announced a research and license agreement with German family-owned pharma major Boehringer Ingelheim to accelerate the development of multiple drug targets.

This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.

The partnership leverages Salipro Biotech’s proprietary Salipro platform technology, which stabilizes membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro-technology to identify potential therapeutic candidates.